Preparation method of exosome hydrogel loaded with miR-144-3p
By loading miR-144-3p into exosomes and dispersing them in hydrogels, a controlled release system was constructed, which solved the problem of uneven bonding between exosomes and hydrogels, and achieved the stability of miR-144-3p Improve sexual and targetedness, providing local and long-term therapeutic effects.
Patent Information
- Application Number
- CN202411188922.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, exosomes are insufficient for miRNA delivery, and the interaction between hydrogels and miRNA is weak, resulting in uneven release of miRNA in the body, making it difficult to achieve long-term therapeutic effects.
By loading miR-144-3p into the exosome and dispersing it evenly in the hydrogel matrix, a controlled release system is constructed, and miR-144-3p is slowly released using the three-dimensional network structure of the hydrogel, and through Adjust the crosslinking degree and polymer matrix type to regulate the release rate.
It significantly improves the stability and targeted delivery efficiency of miR-144-3p, achieves local and long-term drug release, reduces side effects, and enhances the treatment effect on cancer, cardiovascular diseases and other diseases.
Smart Images

Figure CN119033679A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomaterials and drug delivery, and in particular to a method for preparing an exosome hydrogel loaded with miR-144-3p. Background Art
[0002] In recent years, microRNA (miRNA), as a class of small RNA molecules that regulate gene expression at the post-transcriptional level, has received extensive attention. miR-144-3p is a miRNA with multiple biological functions, which plays an important role in the occurrence and development of various diseases, including cancer, cardiovascular disease and neurodegenerative diseases. However, miRNA has poor stability in the body and is easily degraded by nucleases, which limits its clinical application. To overcome this challenge, researchers have proposed using exosomes as delivery vehicles for miRNA. Exosomes are small membrane vesicles secreted by cells, which have natural biocompatibility and low immunogenicity and can protect miRNA from degradation. However, the stability and targeting of miRNA delivered by exosomes alone still have certain limitations. For this reason, hydrogel, as a material with excellent biocompatibility and regulated drug release properties, has gradually become a research hotspot for improving the in vivo delivery effect of miRNA.
[0003] After searching the application number CN202210751176.5, a multifunctional gene carrier and its application in delivering miRNA are disclosed. The present invention belongs to the field of biomedicine technology, and specifically relates to a multifunctional gene carrier of magnetic nanoparticles modified with polyethyleneimine (PEI) coated with fucoidan and its application in delivering miRNA. The nanoparticle core is a Fe3O4 nanoparticle modified with polyethyleneimine (PEI), and the surface is coated with fucoidan by electrostatic adsorption, and the nanoparticle can further bind miRNA by self-assembly for targeted delivery of miRNA. Among them, the fucoidan and miRNA layers are self-assembled into the magnetic Fe3O4 core modified with PEI, and the preparation method is simple, the conditions are mild, and it is easy to operate and repeat. In addition, the fucose composite nanocarrier of the present invention can achieve tissue-targeted delivery with the help of the magnetic nanocore in the carrier, thereby realizing the systematic targeted treatment of tumors. The nanoparticle has the characteristics of non-immunogenicity and high targeting, and has a good application prospect in functional research based on miRNA, treatment of diseases and clinical applications.
[0004] The above-mentioned prior art has the following shortcomings. First, the retention time of the exosome-based miRNA delivery system in the body is limited, and it is difficult to achieve a long-term therapeutic effect. Secondly, although the hydrogel-based miRNA sustained-release system can prolong the release time of miRNA, due to the weak interaction between the hydrogel matrix and miRNA, it is easy to cause miRNA to be excessively released or degraded in a complex in vivo environment. In addition, the existing technical solutions may also face the problem of difficult uniform binding between exosomes and hydrogels in practical applications, thereby affecting the targeting and release efficiency of miRNA.
[0005] Therefore, there is an urgent need for a new technical solution that can effectively combine the advantages of exosomes and hydrogels to enhance the stability of miR-144-3p in vivo, prolong its release time, and improve its delivery efficiency in target tissues, thereby further enhancing the clinical application potential of miR-144-3p. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a method for preparing an exosome hydrogel loaded with miR-144-3p, wherein the method encapsulates miR-144-3p in exosomes and disperses the exosomes loaded with miR-144-3p in a hydrogel matrix to prepare a hydrogel with good biocompatibility and sustained release effect.
[0007] In order to achieve the above object, the present invention adopts the following technical scheme, a method for preparing exosome hydrogel loaded with miR-144-3p, comprising the following steps:
[0008] Step 1: Extraction and purification of exosomes;
[0009] Step 2: loading of miR-144-3p;
[0010] Step 3: Preparation of hydrogel;
[0011] Step 4: Performance testing of hydrogel.
[0012] Preferably, the extraction and purification of exosomes in step 1 comprises the following steps:
[0013] a) selecting HEK293 cells as donor cells;
[0014] b) collecting exosomes in the cell culture supernatant by ultracentrifugation or ultrafiltration;
[0015] c) Exosomes are further purified by gradient centrifugation or size exclusion chromatography.
[0016] Preferably, the loading of miR-144-3p in step 2 comprises the following steps:
[0017] a) preparing miR-144-3p by chemical synthesis or in vitro transcription;
[0018] b) co-incubating miR-144-3p with exosomes;
[0019] c) Load miR-144-3p into exosomes by electroporation or iontophoresis.
[0020] Preferably, the miR-144-3p is prepared by solid phase synthesis technology or T7 RNA polymerase in vitro, and the synthesized miR-144-3p is deprotected, purified and quality tested.
[0021] Preferably, the electroporation method forms micropores on the exosome membrane through a transient high electric field, allowing miR-144-3p to enter the exosome; or the miR-144-3p is transfected into the exosome by an ion transfection method using a cationic polymer or liposome carrier.
[0022] Preferably, the preparation of the hydrogel in step 3 comprises the following steps:
[0023] a) selecting a suitable polymer matrix and dissolving it in a suitable solvent to form a uniform solution;
[0024] b) uniformly dispersing the exosomes loaded with miR-144-3p into the polymer matrix solution;
[0025] c) adding a cross-linking agent to perform a cross-linking reaction to form a three-dimensional network structure;
[0026] d) performing gelation treatment.
[0027] Preferably, the polymer matrix is selected from gelatin, hyaluronic acid or polyethylene glycol (PEG), and the cross-linking agent is selected from a physical cross-linking agent or a chemical cross-linking agent.
[0028] Preferably, the cross-linking reaction time is 1 to 4 hours and the temperature is 4 to 37 degrees Celsius.
[0029] Preferably, the performance test of the hydrogel in step 4 comprises the following steps:
[0030] a) Evaluating the biocompatibility of the hydrogels by in vitro cell culture experiments;
[0031] b) The release kinetics of miR-144-3p from exosome hydrogel was studied by in vitro release experiment.
[0032] Preferably, the in vitro release experiment detects the miR-144-3p content in the release medium by fluorescent quantitative PCR (qPCR) or enzyme-linked immunosorbent assay (ELISA).
[0033] Beneficial Effects
[0034] The present invention provides a method for preparing an exosome hydrogel loaded with miR-144-3p. It has the following beneficial effects:
[0035] (1) The preparation method of the exosome hydrogel loaded with miR-144-3p effectively protects miR-144-3p from degradation by in vitro and in vivo degradative enzymes by loading miR-144-3p into the exosomes, thereby significantly improving its stability. At the same time, since the exosomes have a natural biomembrane structure, they can effectively promote the transmembrane transport of miR-144-3p, enhance its delivery efficiency in target cells, and maintain the biological activity of miR-144-3p.
[0036] (2) The preparation method of the exosome hydrogel loaded with miR-144-3p, by uniformly dispersing the exosomes loaded with miR-144-3p in the hydrogel matrix, the present invention constructs a controllable release system. The three-dimensional network structure of the hydrogel can not only slowly release the miR-144-3p in the exosomes, but also further regulate the release rate of miR-144-3p by adjusting the cross-linking degree of the hydrogel or using different types of polymer matrices, thereby achieving customized release for different treatment needs.
[0037] (3) The method for preparing the exosome hydrogel loaded with miR-144-3p preferably uses natural or synthetic polymers with good biocompatibility, such as gelatin, hyaluronic acid and polyethylene glycol (PEG), etc. These materials have good biodegradability and low immunogenicity. By cross-linking these polymer matrices into hydrogels through cross-linking reactions, the safety of the hydrogel in the body is ensured, and the potential risks of biological toxicity and immune response are reduced.
[0038] (4) The preparation method of the exosome hydrogel loaded with miR-144-3p utilizes this characteristic of exosomes to deliver miR-144-3p to specific tissues or cells, further enhancing the therapeutic effect. In addition, the uniform distribution of the exosomes loaded with miR-144-3p in the hydrogel ensures the sustained release and action of miR-144-3p in the local area, avoids the nonspecific diffusion of the drug, and thus reduces side effects.
[0039] (5) The preparation method of the exosome hydrogel loaded with miR-144-3p. The exosome hydrogel loaded with miR-144-3p provided by the present invention can not only achieve local and long-term release that is difficult to achieve with traditional drugs, but also provide a new gene therapy strategy for the treatment of related diseases such as cancer and cardiovascular disease, opening up a broader prospect for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings described below are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0041] The structures, proportions, sizes, etc. illustrated in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with the technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantial technical significance. Any structural modification, change in proportion or adjustment of size shall still fall within the scope of the technical contents disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.
[0042] Figure 1 It is the overall flow chart of the present invention;
[0043] Figure 2 Detailed steps for extraction and purification of exosomes of the present invention;
[0044] Figure 3 Detailed steps of loading miR-144-3p of the present invention;
[0045] Figure 4 Detailed steps for preparing the hydrogel of the present invention;
[0046] Figure 5 Detailed steps for testing the performance of the hydrogel of the present invention. DETAILED DESCRIPTION
[0047] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0048] Example 1: A method for preparing an exosome hydrogel loaded with miR-144-3p, such as Figures 1 to 5 As shown, the following steps are included:
[0049] Step 1: Extraction and purification of exosomes;
[0050] The extraction source is to select suitable donor cells, preferably HEK293 cells for exosome extraction, collect exosomes in the cell culture supernatant by ultracentrifugation or ultrafiltration, and further purify the exosomes by gradient centrifugation or size exclusion chromatography to obtain a high-purity exosome sample.
[0051] Step 2: loading of miR-144-3p;
[0052] miR-144-3p is prepared by chemical synthesis or in vitro transcription, miR-144-3p is co-incubated with exosomes, and miR-144-3p is loaded into the exosomes by electroporation or ion transfection.
[0053] Step 3: Preparation of hydrogel
[0054] It is preferred to use natural or synthetic polymers with good biocompatibility, such as gelatin, hyaluronic acid, polyethylene glycol (PEG), etc. as the hydrogel matrix, and the polymer matrix is cross-linked by a cross-linking reaction to form a three-dimensional network structure. The cross-linking agent can be a physical cross-linking agent or a chemical cross-linking agent. The exosomes loaded with miR-144-3p are uniformly dispersed in the hydrogel matrix solution, and then gelation treatment is performed to prepare the exosome hydrogel loaded with miR-144-3p.
[0055] Step 4: Hydrogel performance testing
[0056] In vitro cell culture experiments were used to evaluate the biocompatibility of the hydrogel, and in vitro release experiments were used to study the release kinetics of miR-144-3p from exosome hydrogel.
[0057] Example 2, based on the above examples, in step 1, in the extraction of exosomes, the selection of suitable donor cells is the key. HEK293 cells are preferably used because they have a high exosome secretion capacity and a stable genetic background. Before cell culture, ensure that the exogenous exosomes in the culture medium are removed to avoid contamination of the sample. DMEM culture medium containing exosome-free fetal bovine serum is generally used, and the culture conditions are 37 degrees Celsius and 5% carbon dioxide concentration to culture cells to 70%-80% confluence. Exosomes are mainly extracted by ultracentrifugation or ultrafiltration.
[0058] The steps of ultracentrifugation are as follows:
[0059] The invention collects the cell culture supernatant, and first centrifuges it at 300 g of centrifugal force (g-force) for 5 minutes to remove cell debris.
[0060] The supernatant was transferred to a new tube and centrifuged at 2000 g for 20 minutes to remove larger cell debris and residual cells.
[0061] The invention further centrifuged at 10000 g for 30 minutes to remove cell debris and macromolecular aggregates.
[0062] The invention finally centrifuged the supernatant at 100000g for 70 minutes to precipitate the exosomes. In order to avoid the loss of exosomes, the supernatant was carefully discarded after centrifugation and the precipitate was retained.
[0063] The operating steps of ultrafiltration are as follows:
[0064] The cell culture supernatant was collected and filtered through a 0.22 μm filter to remove cell debris and macromolecules.
[0065] Using ultrafiltration equipment, place the sample in a 10 kDa ultrafiltration membrane and centrifuge at 3000 g for 20 minutes to concentrate the sample to the required volume.
[0066] The solution was filtered again through a 0.22 μm filter membrane to remove possible contaminants and particles to obtain exosome concentrate.
[0067] To obtain highly pure exosomes, gradient centrifugation or size exclusion chromatography was used for further purification.
[0068] The steps for gradient centrifugation are as follows:
[0069] Prepare 30%, 45%, and 60% sucrose solutions to form a sucrose gradient solution.
[0070] The exosome suspension was gently layered on top of the 60% sucrose solution, and then 45% and 30% sucrose solutions were added layer by layer to form a continuous gradient.
[0071] The samples were centrifuged at 100,000 g for 18 hours. After centrifugation, the liquids of different density layers were carefully separated, and the exosomes were located in the layer between 45% and 60%.
[0072] The exosome layer was collected, PBS solution was added, and centrifuged at 100,000 g for 70 min to remove sucrose and obtain highly pure exosomes.
[0073] The steps for size exclusion chromatography are as follows:
[0074] Prepare an equilibrated size exclusion chromatography column using Sepharose CL-4B or Sephacryl S-400 as the packing material.
[0075] The concentrated exosome solution was loaded onto the chromatographic column and separated at a slow flow rate using PBS solution as the eluent.
[0076] Different fractions of elution were collected and the presence of exosomes was determined using protein quantification analysis, with high purity of exosomes appearing in the earlier elution fractions.
[0077] The exosome-containing fractions were collected and centrifuged at 100,000 g for 70 min to precipitate and concentrate the exosome samples.
[0078] During the entire extraction and purification process, all operations were performed at 4 degrees Celsius, and sterile techniques were used in each step to avoid interference from external contaminants. The final exosome samples should be verified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) or Western Blot to ensure their purity and structural integrity.
[0079] Example 3. Based on Example 1 and Example 2, in step 2, in the process of loading miR-144-3p into exosomes, the main steps used include preparation of miR-144-3p, co-incubation with exosomes, and effective introduction of miR-144-3p into exosomes by electroporation or ion transfection technology.
[0080] The preparation of miR-144-3p is completed by chemical synthesis or in vitro transcription. The chemical synthesis method uses solid phase synthesis technology to synthesize the nucleotide sequence in sequence to the target miRNA length. The synthesized miR-144-3p is deprotected, purified and quality tested to ensure its sequence integrity and functionality. The in vitro transcription method uses a DNA template to synthesize miR-144-3p in vitro by T7 RNA polymerase. The specific operation is to first amplify the DNA template containing the T7 promoter by PCR, and then mix the template with NTPs and T7 RNA polymerase. The reaction time is 2 hours and the temperature is set at 37 degrees Celsius. After the reaction, miR-144-3p is purified by phenol chloroform extraction and further purified by high performance liquid chromatography (HPLC) to ensure the high purity of miRNA.
[0081] Before loading miR-144-3p, miR-144-3p needs to be co-incubated with the extracted and purified exosomes. A certain concentration of miR-144-3p is selected and mixed with a certain amount of exosomes to ensure sufficient contact between the two. The specific operation is to mix 10 micrograms of exosomes with 20 micromoles of miR-144-3p in a volume of 500 microliters of PBS buffer, gently stir to mix, and incubate the mixture at 37 degrees Celsius for 30 minutes. During this process, miR-144-3p will naturally adsorb to the surface of the exosomes.
[0082] In order to effectively introduce miR-144-3p into exosomes, electroporation or ion transfection technology is selected.
[0083] Electroporation uses a transient high electric field to form micropores on the exosome membrane, allowing miR-144-3p to enter the exosome. During operation, the co-incubated exosome-miRNA mixture is added to the electroporation buffer, which contains 20mM HEPES, 135mM KCl, 2mM MgCl2, and the pH is adjusted to 7.2. The mixture is transferred to the electrodes of the electroporator, and the voltage is set to 500 volts, the pulse duration is 5 milliseconds, the number of pulses is 5 times, and the interval time is 1 second. After the electroporation is completed, the sample is immediately transferred to ice for 10 minutes to stabilize the exosome membrane. Finally, the treated sample is centrifuged at 100000g for 70 minutes to remove the unabsorbed miRNA and recover the loaded exosomes.
[0084] The ion transfection method uses cationic polymers or liposomes as carriers to transfect miR-144-3p into exosomes. During the operation, the ion transfection complex is first prepared, and the cationic liposomes (such as Lipofectamine 2000) are mixed with miR-144-3p in a volume ratio of 1:1, and allowed to stand at room temperature for 20 minutes to form a miRNA-liposome complex. Then, the complex is added to the co-incubated exosome solution and incubated at room temperature for 15 minutes. At this point, the liposome-encapsulated miR-144-3p will gradually fuse into the exosome membrane, thereby achieving the effective loading of miR-144-3p. Finally, the sample is centrifuged at 100,000 g for 70 minutes to remove excess complexes and recover the loaded exosomes.
[0085] After miR-144-3p loading is completed, fluorescent quantitative PCR (qPCR) is used to verify that miR-144-3p has successfully entered the exosomes. During verification, the loaded exosomes are lysed, miRNA is extracted, and qPCR analysis is performed. The results should show a specific concentration of miR-144-3p, indicating the success of the loading process. Efficient operation of this step not only ensures the functional integrity of the exosomes, but also significantly improves the biological activity of miR-144-3p in downstream applications.
[0086] Example 4, based on Example 1, Example 2 and Example 3, in step 3, when preparing the exosome hydrogel loaded with miR-144-3p, first select a suitable polymer matrix. Common matrices include gelatin, hyaluronic acid and polyethylene glycol (PEG). These materials are widely used in the preparation of hydrogels due to their good biocompatibility and adjustable physicochemical properties. First, the polymer matrix needs to be dissolved in an appropriate solvent, such as dissolving gelatin in warm water until it is completely dissolved and forms a uniform solution. Next, select a suitable cross-linking agent, and the choice of the cross-linking agent depends on the properties of the polymer used and the target hydrogel. The cross-linking agent can be a physical cross-linking agent, such as physical cross-linking caused by temperature changes, or a chemical cross-linking agent, such as glutaraldehyde or a photoinitiator, which forms chemical bonds between polymer matrix molecules through a cross-linking reaction, thereby constructing a three-dimensional network structure.
[0087] Before adding the cross-linker, the exosomes loaded with miR-144-3p are evenly dispersed into the polymer matrix solution to ensure uniform distribution of the exosomes in the solution. This can be achieved by continuously stirring the solution with a magnetic stirrer while keeping the temperature and pH of the solution stable. The stirring speed and time should be optimized according to the viscosity of the solution and the dispersibility of the exosomes. It is recommended to stir at a speed of 300 to 500 revolutions per minute for 30 to 60 minutes to ensure that the exosomes and the polymer are fully mixed. Thereafter, the cross-linker is added to the mixed solution of exosomes and polymers, and gentle stirring is maintained to promote the cross-linking reaction. The time and temperature of the cross-linking reaction need to be adjusted according to the specific polymer and cross-linker. For example, the cross-linking of gelatin can be carried out at a temperature of 4 to 37 degrees Celsius and the reaction time is 1 to 4 hours to ensure the formation of a stable three-dimensional network structure.
[0088] After the cross-linking reaction is completed, gelation treatment is performed. The mixed solution is poured into a mold and allowed to stand at an appropriate temperature until it is completely gelled. The gelation time and conditions should be adjusted according to the specific materials and application requirements. After the gelation process is completed, the exosome hydrogel loaded with miR-144-3p is taken out and subjected to appropriate post-treatment, such as washing to remove residual substances that are not involved in the reaction. Finally, the obtained hydrogel can be freeze-dried as needed to improve its stability and storage life, or directly used in downstream biomedical applications.
[0089] Example 5, based on Example 1, Example 2, Example 3 and Example 3, in step 4, after the hydrogel preparation is completed, the performance test of the hydrogel is required to evaluate its biocompatibility and the release kinetics of miR-144-3p. First, the biocompatibility test is carried out by in vitro cell culture experiments. Select a suitable cell line, such as human embryonic kidney cells (HEK293) or human mesenchymal stem cells (hMSC), culture the cells in an appropriate culture medium (such as DMEM culture medium, containing 10% fetal bovine serum), and keep the cell culture conditions stable (37 degrees Celsius, 5% carbon dioxide environment). When the cells reach 80-90% confluence, the exosome hydrogel loaded with miR-144-3p is added to the cell culture dish at an appropriate concentration. A control group was set up, and a hydrogel without miR-144-3p or exosomes was used as a control. The morphological changes of the cells were observed under a microscope, and the survival rate of the cells was evaluated using CCK-8 or MTT kits. The optical density values at specific time points were measured, the cell proliferation rate and survival rate were calculated, and the biocompatibility of the hydrogel was evaluated.
[0090] Next, the release kinetics of miR-144-3p by exosome hydrogel was studied by in vitro release experiment. In this process, the prepared hydrogel was first placed in a release medium containing phosphate buffered saline (PBS). Ensure that the pH value of the release medium is consistent with the in vivo environment (usually 7.4), and maintain constant temperature conditions (37 degrees Celsius) to simulate the in vivo release environment. Sampling was performed at specific time points (such as 0 hours, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, etc.), and the release medium samples were collected. To avoid interference between samples, an equal volume of fresh buffer should be added in time after sampling.
[0091] At each time point, the miR-144-3p content in the release medium was detected by fluorescent quantitative PCR (qPCR) or enzyme-linked immunosorbent assay (ELISA), and the amount of miR-144-3p released at each time point was quantitatively analyzed by the standard curve. Combined with the cumulative amount of miR-144-3p in the release medium, the time-release curve was drawn to calculate the release rate of miR-144-3p. The zero-order release equation (M_t / M_∞=kt) or the first-order release kinetic model (ln(1-M_t / M_∞)=-kt) is usually used to fit the data, where M_t is the mass of miR-144-3p released at a certain moment, M_∞ is the total amount of miR-144-3p finally released, and k is the release rate constant. The release characteristics of the hydrogel for miR-144-3p are analyzed by the slope k of the fitted straight line.
[0092] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A method for preparing an exosome hydrogel loaded with miR-144-3p, characterized in that: The following steps are involved: Step 1: Extraction and purification of exosomes; Step 2: loading of miR-144-3p; Step 3: Preparation of hydrogel; Step 4: Performance testing of hydrogel.
2. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 1, characterized in that: The exosome extraction and purification in step 1 includes the following steps: a) selecting HEK293 cells as donor cells; b) collecting exosomes in the cell culture supernatant by ultracentrifugation or ultrafiltration; c) Exosomes are further purified by gradient centrifugation or size exclusion chromatography.
3. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 1 or 2, characterized in that: The loading of miR-144-3p in step 2 comprises the following steps: a) preparing miR-144-3p by chemical synthesis or in vitro transcription; b) co-incubating miR-144-3p with exosomes; c) Load miR-144-3p into exosomes by electroporation or iontophoresis.
4. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 3, characterized in that: The miR-144-3p is prepared by solid phase synthesis technology or T7 RNA polymerase in vitro, and the synthesized miR-144-3p is deprotected, purified and quality tested.
5. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 3, characterized in that: The electroporation method forms micropores on the exosome membrane through a transient high electric field, allowing miR-144-3p to enter the exosome; or the ion transfection method uses a cationic polymer or liposome carrier to transfect miR-144-3p into the exosome.
6. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 1, characterized in that: The preparation of the hydrogel in step 3 comprises the following steps: a) selecting a suitable polymer matrix and dissolving it in a suitable solvent to form a uniform solution; b) uniformly dispersing the exosomes loaded with miR-144-3p into the polymer matrix solution; c) adding a cross-linking agent to perform a cross-linking reaction to form a three-dimensional network structure; d) performing gelation treatment.
7. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 6, characterized in that: The polymer matrix is selected from gelatin, hyaluronic acid or polyethylene glycol (PEG), and the cross-linking agent is selected from a physical cross-linking agent or a chemical cross-linking agent.
8. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 6 or 7, characterized in that: The cross-linking reaction time is 1 to 4 hours, and the temperature is 4 to 37 degrees Celsius.
9. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 1, characterized in that: The performance test of the hydrogel in step 4 comprises the following steps: a) Evaluating the biocompatibility of the hydrogels by in vitro cell culture experiments; b) The release kinetics of miR-144-3p from exosome hydrogel was studied by in vitro release experiment.
10. The method for preparing an exosome hydrogel loaded with miR-144-3p according to claim 9, characterized in that: The in vitro release experiment detects the miR-144-3p content in the release medium by fluorescent quantitative PCR (qPCR) or enzyme-linked immunosorbent assay (ELISA).
Citation Information
Patent Citations
miR-144-3P and application of target gene thereof for preparing medicine for adjusting human cardiac fibroblast function
CN108992457A
Target miRNA-loaded mesenchymal stem cell exosome, dressing applying same, and preparation method of target miRNA-loaded mesenchymal stem cell exosome
CN109112110A
Temperature-sensitive exosome system with maternal imprinting and preparation method and application of temperature-sensitive exosome system with maternal imprinting
CN111450117A
The human miR-144-3p inhibits malignancy of prostate cancer induced by acidosis
CN111494633A
Cited By
Exosome-loaded composite hydrogel and preparation method thereof
CN120501695A
A loaded exosome composite hydrogel and a preparation method thereof
CN120501695B
